Mononine

01/01/1995 - "These studies indicate that Mononine is safe and effective in the treatment of hemorrhagic episodes in patients with hemophilia B."
02/01/1992 - "Mononine was evaluated for in vivo recovery, half-life, and for its safety and efficacy in 10 patients with hemophilia B. "
01/01/1995 - "Pharmacokinetic variables were studied in severe hemophilia B patients: Nanotiv was compared with Preconativ; Immunine was compared with Prothromplex TIM4 in crossover studies; and Mononine was tested in a single-drug study. "
11/15/1993 - "In vivo, Nanotiv was compared with Preconativ and Immunine with Prothromplex TIM4 in crossover studies in patients with severe hemophilia B, and Mononine was tested in a single drug study. "
03/01/2003 - "Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B."

01/01/1995 - "The only thrombotic complication attributed to Mononine in the two studies was an episode of phlebitis at the site of an intravenous line in one patient. "

01/01/1995 - "Patients with hepatitis and a prior history of thrombosis with PCCs tolerated Mononine with no evidence of thrombosis. "

01/01/1995 - "Patients with hepatitis and a prior history of thrombosis with PCCs tolerated Mononine with no evidence of thrombosis. "

02/01/1992 - "Patients who used Mononine as their sole therapeutic material during the 12-month period showed an excellent response in hemostasis for their bleeding episodes. "